7Baggers

We provide you with 20 years of free, institutional-grade data for ADPT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ADPT. Explore the full financial landscape of ADPT stock.

Reported DateCIKTickerType
2024-02-291478320ADPT10-KUrl
2023-11-091478320ADPT10-QUrl
2023-08-021478320ADPT10-QUrl
2023-05-031478320ADPT10-QUrl
2023-02-141478320ADPT10-KUrl
2022-11-031478320ADPT10-QUrl
2022-08-031478320ADPT10-QUrl
2022-05-041478320ADPT10-QUrl
2022-02-151478320ADPT10-KUrl
2021-11-031478320ADPT10-QUrl
2021-08-041478320ADPT10-QUrl
2021-05-051478320ADPT10-QUrl
2021-02-241478320ADPT10-KUrl
2020-11-101478320ADPT10-QUrl
2020-08-101478320ADPT10-QUrl
2020-05-121478320ADPT10-QUrl
2020-02-261478320ADPT10-KUrl
2020-01-211478320ADPTS-1Url
2019-11-121478320ADPT10-QUrl
2019-08-131478320ADPT10-QUrl
2019-05-301478320ADPTS-1Url

Adaptive Biotechnologies Corporation
(NASDAQ:ADPT) 

ADPT stock logo

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new progno...

Founded: 2009
IPO Price: $20 (Jun 27, 2019)
Full Time Employees: 453
CEO: Chad Robins  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about ADPT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.